GHK-Cu is one of the most extensively studied small peptides in dermatological and molecular biology literature. First isolated from human plasma, it is a tripeptide with a strong affinity for copper ions, and much of the research interest centers on how that copper-binding property influences cellular behavior in laboratory models.

What GHK-Cu is

Chemically, GHK is glycyl-L-histidyl-L-lysine, a three-amino-acid sequence. The histidine residue coordinates a copper(II) ion to form the GHK-Cu complex. Researchers frequently distinguish between the free peptide and the copper complex because the metal coordination is thought to be central to several of the effects observed in cell culture.

  • Sequence: Gly-His-Lys
  • Notable feature: high-affinity copper(II) binding
  • Origin: identified in human plasma and later synthesized

What the research describes

In-vitro studies have associated GHK-Cu with the modulation of extracellular matrix proteins, including collagen and glycosaminoglycans, in cultured fibroblasts. Gene-expression profiling experiments have reported broad transcriptional changes, which is part of why the peptide is sometimes framed as a signaling molecule rather than a simple nutrient.

Most of the mechanistic data comes from cell culture and animal models; extrapolation to human outcomes remains speculative and is not established.

Some observational human studies have reported that free GHK levels in plasma appear to decline with age, which has fueled hypotheses about its role in tissue maintenance. These are correlational findings and do not demonstrate causation or therapeutic benefit.

Where the evidence stops

It is important to emphasize that rigorous, large-scale human clinical trials establishing efficacy for any specific indication are limited. Much of the enthusiasm around GHK-Cu is grounded in mechanistic plausibility and preclinical signals rather than confirmed clinical outcomes. Readers evaluating the literature should note the difference between what is observed in a dish and what is proven in people.

  • Bulk of evidence is preclinical (in-vitro and animal).
  • Human data is largely observational or small-scale.
  • No established therapeutic claims should be drawn from this summary.

For research and educational purposes only. This is not medical advice, and peptides referenced are sold for laboratory research use only.